The role of PPAR-γ and its interaction with COX-2 in pancreatic cancer

PPAR Research

Volumn , Issue , 2008, Pages

  Eibl, Guido ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CYCLOOXYGENASE 2 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; POLYUNSATURATED FATTY ACID; TROGLITAZONE;

CANCER GROWTH; DRUG ACTIVITY; DRUG ANTAGONISM; HUMAN; NONHUMAN; PANCREAS CANCER; REVIEW;

EID: 47349128912     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/326915     Document Type: Review

References (55)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J., Cancer statistics, 2007 CA: A Cancer Journal for Clinicians 2007 57 1 43 66
2. Kazanjian K. K., Hines O. J., Duffy J. P., Improved survival for adenocarcinoma of the pancreas after pancreaticoduodenectomy Gastroenterology 2005 128 A813 A814
3. Boeck S., Ankerst D. P., Heinemann V., The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis Oncology 2008 72 5-6 314 321
4. Shore S., Raraty M. G. T., Ghaneh P., Neoptolemos J. P., Review article: chemotherapy for pancreatic cancer Alimentary Pharmacology & Therapeutics 2003 18 11-12 1049 1069
5. Moore M. J., Goldstein D., Hamm J., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology 2007 25 15 1960 1966
6. Lowenfels A. B., Maisonneuve P., Epidemiology and risk factors for pancreatic cancer Best Practice and Research in Clinical Gastroenterology 2006 20 2 197 209
7. Giovannucci E., Michaud D., The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas Gastroenterology 2007 132 6 2208 2225
8. Russo A., Autelitano M., Bisanti L., Metabolic syndrome and cancer risk European Journal of Cancer 2008 44 2 293 297
9. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
10. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease Trends in Pharmacological Sciences 2005 26 5 244 251
11. Evans R. M., Barish G. D., Wang Y.-X., PPARs and the complex journey to obesity Nature Medicine 2004 10 4 355 361
12. Pakala R., Kuchulakanti P., Rha S.-W., Cheneau E., Baffour R., Waksman R., Peroxisome proliferator-activated receptor γ: its role in metabolic syndrome Cardiovascular Radiation Medicine 2004 5 2 97 103
13. Semple R. K., Chatterjee V. K. K., O'Rahilly S., PPAR γ and human metabolic disease Journal of Clinical Investigation 2006 116 3 581 589
14. Quinn C. E., Hamilton P. K., Lockhart C. J., McVeigh G. E., Thiazolidinediones: effects on insulin resistance and the cardiovascular system British Journal of Pharmacology 2008 153 4 636 645
15. Kepez A., Oto A., Dagdelen S., Peroxisome proliferator-activated receptor- γ: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis BioDrugs 2006 20 2 121 135
16. Pfüützner A., Schneider C. A., Forst T., Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects Expert Review of Cardiovascular Therapy 2006 4 4 445 459
17. Walcher D., Marx N., Insulin resistance and cardiovascular disease: the role of PPAR γ activators beyond their anti-diabetic action Diabetes & Vascular Disease Research 2004 1 2 76 81
18. Han S., Roman J., Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics? Anti-Cancer Drugs 2007 18 3 237 244
19. Krishnan A., Nair S. A., Pillai M. R., Biology of PPAR γ in cancer: a critical review on existing lacunae Current Molecular Medicine 2007 7 6 532 540
20. Kristiansen G., Jacob J., Buckendahl A.-C., Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times Clinical Cancer Research 2006 12 21 6444 6451
21. Lehrke M., Lazar M. A., The many faces of PPAR γ Cell 2005 123 6 993 999
22. Galli A., Mello T., Ceni E., Surrenti E., Surrenti C., The potential of antidiabetic thiazolidinediones for anticancer therapy Expert Opinion on Investigational Drugs 2006 15 9 1039 1049
23. Grommes C., Landreth G. E., Heneka M. T., Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists The Lancet Oncology 2004 5 7 419 429
24. Panigrahy D., Shen L. Q., Kieran M. W., Kaipainen A., Therapeutic potential of thiazolidinediones as anticancer agents Expert Opinion on Investigational Drugs 2003 12 12 1925 1937
25. Yang K., Fan K.-H., Lamprecht S. A., Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in A p c 1638 N/+ M l h 1 + /-double mutant mice International Journal of Cancer 2005 116 4 495 499
26. Choi I. K., Kim Y. H., Kim J. S., Seo J. H., PPAR- γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo Investigational New Drugs 2008 26 3 283 288
27. Saez E., Rosenfeld J., Livolsi A., PPAR γ signaling exacerbates mammary gland tumor development Genes and Development 2004 18 5 528 540
28. Lefebvre A.-M., Chen I., Desreumaux P., Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J- APC M i n /+ mice Nature Medicine 1998 4 9 1053 1057
29. Pino M. V., Kelley M. F., Jayyosi Z., Promotion of colon tumors in C57BL/6J- APC M i n /+ mice by thiazolidinedione PPAR γ agonists and a structurally unrelated PPAR γ agonist Toxicologic Pathology 2004 32 1 58 63
30. Ceni E., Mello T., Tarocchi M., Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells World Journal of Gastroenterology 2005 11 8 1122 1130
31. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., Kiyosawa K., Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR γ ligand troglitazone Pancreas 2002 24 1 1 7
32. Hashimoto K., Farrow B. J., Evers B. M., Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell Line MIA PaCa-2 Pancreas 2004 28 2 153 159
33. Galli A., Ceni E., Crabb D. W., Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR γ independent mechanisms Gut 2004 53 11 1688 1697
34. Motomura W., Nagamine M., Tanno S., Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells Journal of Gastroenterology 2004 39 5 461 468
35. Rumi M. A. K., Ishihara S., Kazumori H., Kadowaki Y., Kinoshita Y., Can PRAR γ ligands be used in cancer therapy? Current Medicinal Chemistry 2004 4 6 465 477
36. Weng J.-R., Chen C.-Y., Pinzone J. J., Ringel M. D., Chen C.-S., Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones Endocrine-Related Cancer 2006 13 2 401 413
37. Feinstein D. L., Spagnolo A., Akar C., Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochemical Pharmacology 2005 70 2 177 188
38. Samudio I., Konopleva M., Hail N. Jr., 2-cyano-3,12-dioxooleana-1,9-dien- 28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer Journal of Biological Chemistry 2005 280 43 36273 36282
39. Abdelrahim M., Newman K., Vanderlaag K., Samudio I., Safe S., 3, 3 ′ -diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5 Carcinogenesis 2006 27 4 717 728
40. Eibl G., Wente M. N., Reber H. A., Hines O. J., Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis Biochemical and Biophysical Research Communications 2001 287 2 522 529
41. Sawai H., Liu J., Reber H. A., Hines O. J., Eibl G., Activation of peroxisome proliferator-activated receptor- γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system Molecular Cancer Research 2006 4 3 159 167
42. Eibl G., Takata Y., Boros L. G., Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor Cancer Research 2005 65 3 982 990
43. Margeli A., Kouraklis G., Theocharis S., Peroxisome proliferator activated receptor- γ (PPAR- γ) ligands and angiogenesis Angiogenesis 2003 6 3 165 169
44. Biscetti F., Gaetani E., Flex A., Selective activation of peroxisome proliferator-activated receptor (PPAR) α and PPAR γ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism Diabetes 2008 57 5 1394 1404
45. Takeuchi Y., Takahashi M., Sakano K., Suppression of N -nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor γ Carcinogenesis 2007 28 8 1692 1696
46. Smith W. L., Marnett L. J., DeWitt D. L., Prostaglandin and thromboxane biosynthesis Pharmacology and Therapeutics 1991 49 3 153 179
47. Negishi M., Sugimoto Y., Ichikawa A., Molecular mechanisms of diverse actions of prostanoid receptors Biochimica et Biophysica Acta 1995 1259 1 109 120
48. Negishi M., Katoh H., Cyclopentenone prostaglandin receptors Prostaglandins and Other Lipid Mediators 2002 68-69 611 617
49. Spencer A. G., Woods J. W., Arakawa T., Singer I. I., Smith W. L., Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy Journal of Biological Chemistry 1998 273 16 9886 9893
50. Eibl G., Reber H. A., Hines O. J., Go V. L. W., COX and PPAR: possible interactions in pancreatic cancer Pancreas 2004 29 4 247 253
51. Kliewer S. A., Sundseth S. S., Jones S. A., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323
52. Glover S., Bayburt T., Jonas M., Chi E., Gelb M. H., Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen Journal of Biological Chemistry 1995 270 25 15359 15367
53. Kan H., Ruan Y., Malik K. U., Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells Molecular Pharmacology 1996 50 5 1139 1147
54. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs Journal of Biological Chemistry 1997 272 6 3406 3410
55. Funahashi H., Satake M., Dawson D., Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor Cancer Research 2007 67 15 7068 7071